Corvus PharmaceuticalsCRVS
Recorded

Corvus Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration19 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Jefferies 2026 Healthcare Conference. Please welcome Jeff Arcara, Chief Business Officer at Corvus.

Jeff ArcaraChief Business Officer

Thank you. Thank you. My name is Jeff Arcara. I am the Chief Business Officer for Corvus Pharmaceuticals. This afternoon, we will spend a few minutes providing an overview of Corvus as well as our pipeline, and we will focus specifically on soquelitinib, which is our novel oral highly selective ITK inhibitor. We will also review some of our clinical data as well as some of the key clinical data readouts that we will see starting in Q1 2027 and throughout the entire year. This is our forward-looking statement. You can review this statement along with our slides on our investor website. First, who is Corvus? We are a clinical-stage company developing novel immune modulators for the treatment of cancer and immune diseases.

Jeff ArcaraChief Business Officer

We have our lead program, soquelitinib, which is in a phase III registrational trial for peripheral T-cell lymphoma, which is a really tough cancer to treat, as well as a phase II program in moderate to severe atopic dermatitis. That is called the SIERRA1 trial, and both those trials are enrolling. Soquelitinib represents a pipeline and a product opportunity for us, so we have a number of additional clinical trials that we are running, including HS, which just started enrolling last month, as well as we are going to start an asthma study in the beginning of 2027. ITK is a platform technology for us. We have a number of next-generation and backup compounds in development, and we have strong IP protection through November of 2037, and that is 2042 if you include pharmaceutical extensions.

Jeff ArcaraChief Business Officer

Finally, on the bottom of the slide, you can see we have a Chinese partner, Angel Pharmaceuticals, who we own 49% of, and they are running clinical trials with soquelitinib in China as well, including an AD study, which we will talk about in a few slides. First, why ITK? ITK stands for interleukin-2-inducible T-cell kinase. It is involved in T-cell receptor signaling and differentiation. If you look at the left-hand side of the slide, you can see naive CD4 T cells can differentiate into Th1, Th2, or Th17 cells. If you look at the right-hand side of the slide, essentially how soquelitinib works is that we block Th2 and Th17 and their respective cytokines. So think IL-4, 5, and 13, like DUPIXENT. Think IL-17, like Bimzelx. What that does is that skews the immune response towards the Th1 cells, which are involved in fighting cancer and viral elimination.

Jeff ArcaraChief Business Officer

It is also important to note, if you look at the upper right-hand side of the slide, we are very selective for ITK, but we spare RLK. RLK stands for resting lymphocyte kinase. It is a redundant T-cell signaling pathway, and by sparing that, we help preserve the Th1 response. If you look at the lower right hand of the slide, in addition to us blocking Th17 and IL-17, we have shown that we can shift or switch Th17 cells to become active Treg cells. In essence, we are taking the foot off the gas by lowering the cytokines, and we are putting the foot on the brake at the same time by increasing Tregs. We are modulating or rebalancing the immune system. We are not suppressing it.

Jeff ArcaraChief Business Officer

How do we accomplish that? We accomplish that through some really smart science and making a very targeted and selective drug. As you can see in the center of that slide, you can see the kinome tree showing specific for ITK. If you look at the upper left-hand corner of that slide, that is a specific binding table. KD, the lower the KD, the more strong the binding. The first row, ITK, 6.5. Very strong binding for ITK. If you look at the very bottom, RLK, 2700. So we are highly selective for ITK over RLK, as well as other TEC family kinases. That is important not only for efficacy, but also for safety. Why do I say that? ITK has very limited tissue distribution. It is found primarily on NK cells and T cells. You can see we are very selective just for ITK.

Jeff ArcaraChief Business Officer

With that, we expect limited off-target effects because of that, and that has actually played out in our clinical data. We have seen a very good safety profile comparable to placebo. How does this compare to currently approved therapeutic agents? Because we work more upstream, blocking Th2 and Th17, you can see in that first row, the green across, we block a broader set of cytokines. This does two things for us. It allows us to treat a broader set of patients. For example, patients that may have failed prior therapies or patients that have a disease that involves both Th2 and Th17. Think atopic dermatitis, think asthma. It also allows us to treat a broader set of patients, or excuse me, a broader set of diseases. In addition to Th2 and Th17-driven diseases, we believe we can treat IL-5-driven diseases as well as fibrotic diseases.

Jeff ArcaraChief Business Officer

We actually have preclinical data models in atopic dermatitis, asthma, psoriasis, systemic sclerosis, IPF, and colitis models, and others. There is a lot more we can do with soquelitinib, but also with our next-generation ITK inhibitors. When you look at all these diseases together, they make up a very significant targeted addressable market, 130 million patients across the G7. About 20 million of those would be our more severe, moderate to severe patients that we would treat. On the right-hand side, you can see that market is projected to be $170 billion, with just a fraction of that being orals, only 10%. A significant opportunity for a novel, safe oral therapy in I&I diseases. Let us take a closer look at our pipeline and what is the clinical data that is going to drive our readouts in 2027.

Jeff ArcaraChief Business Officer

At the top of the slide, I mentioned we have a phase III trial in peripheral T-cell lymphoma. That is actually in relapsed and refractory PTCL. That is a really tough disease to treat. Our current standard of care is inadequate. It is not tolerated very well. It does not work very well. NCCN guidelines actually recommend a clinical trial in place of those drugs currently. So, significant unmet need for us to fill. You can see in that center column, we have a futility analysis that will be happening in Q1 2027. We also have orphan drug designation and fast track designation. In terms of phase II trials, we have the atopic dermatitis trial, that is the SIERRA1 trial. That will read out in Q3 of 2027. And then we also will be starting an asthma trial that will start in Q1.

Jeff ArcaraChief Business Officer

Because of the mechanism of action that we just talked about, we are going to actually enroll both T2 and non-T2 asthma patients, because we can block both Th2 and Th17. What we will do is that we will have an interim analysis, and we will look at each of those groups separately, and if we see a non-performing group, we will drop them from the trial so we can continue the trial to keep going. In terms of phase I in the middle, you can see we have an HS study that just started. That is a Th17-driven disease, right? You look at Bimzelx, which blocks IL-17A and F. This is the first time we are going into a Th17 disease in HS, so we have designed this as a true proof of concept study, but it will read out relatively quickly in the first half of 2027.

Jeff ArcaraChief Business Officer

And at the bottom, Angel, our partner in China, will look more into the study. They have their first cohort done and enrolled, and that data will read out in March of 2027. The second cohort will start enrolling now in November, and that data should be available in the second half of 2027. Speaking of AD, let us look at the clinical data a little closer. So this is our phase I trial design. Just to base set everyone, there was a total of 72 patients with moderate to severe atopic dermatitis, 48 on drug, 24 on placebo. We did four cohorts. Cohorts one and two are the low-dose cohorts. They were randomized 3:1, so 12 on drug, four on placebo. These were four weeks of treatment, and it was a QD versus BID. Cohorts three and four are our higher dose.

Jeff ArcaraChief Business Officer

That is four weeks of treatment and eight weeks of treatment respectively, for again, a total of 72 patients. If you look at the study design on the right, it is pretty standard. Its safety is the primary endpoint, but we also looked at change in EASI score, EASI-75, 90, and IGA 0/1. It is also important to note there were no concomitant steroids, so this is monotherapy data that we are showing. So what did the trial show? We saw that with increasing the dose and increasing the duration, we saw deeper responses and more durable responses. So on the left-hand side is our first three cohorts. That was, again, four weeks of data. Really, the focus is on the right-hand side. That is our cohort four data. Again, that was eight weeks of data of treatment. It is the higher dose. If you look at that blue bar, that is EASI-75.

Jeff ArcaraChief Business Officer

We saw a 75% response rate versus placebo at 20. That's actually comparable to a JAK level of efficacy. If you look at the right-hand side, the light blue bar, 33%, that's IGA 0/1. That's actually comparable to a biologic level. Right now, we're sitting somewhere between a biologic and a JAK in terms of level of efficacy. Again, that's for cohort four. If you look at all of the patients together, on the left-hand side, you can see the orange line is the placebo, cohorts one through four. The blue line is the active group, soquelitinib. You can see a significant separation from placebo starting as early as two weeks. On the right-hand side, as a reminder, we had 35% of our patients having a prior systemic therapy. That's what you're seeing on the right side. It works. soquelitinib worked just as well, but what happened is you can see placebo does not work as well, what you would expect in terms of treating sicker patients.

Jeff ArcaraChief Business Officer

Both of those are statistically significant separations from placebo. We also looked at true treatment-resistant patients. We did case studies. We found six patients in total in cohorts three and four that actually were resistant to drugs like DUPIXENT or Rinvoq, even OX40 that is no longer with us. The four patients with soquelitinib, three of the four responded to therapy, as you can see on the right-hand side, and the two placebos actually flared. In addition to looking at response, we also looked at durability of treatment. What you can see on the left-hand side is the first three cohorts, EASI-75, just under 40%. In the gray box, that's off of treatment.

Jeff ArcaraChief Business Officer

90 days off of treatment, we saw that the response was still at the same level. On the right-hand side is cohort four. Again, that was a 75% response. In the gray box, you can see 30 days off of therapy, they maintain their level of response. This is interesting for us to look at and think about. This is where the Treg story starts to come into play if we can create more of a durable response by increasing Tregs. We're going to look at this more deeply in our phase II SIERRA1 trial. We have a 90-day follow-up period. We're not the only ones that looked at this. The JAKs and the biologics looked at this as well, and you can see on this slide, essentially after stopping treatment with JAKs or a biologic, patients rebounded as quickly as one week.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day